MX2013013281A - Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca. - Google Patents

Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca.

Info

Publication number
MX2013013281A
MX2013013281A MX2013013281A MX2013013281A MX2013013281A MX 2013013281 A MX2013013281 A MX 2013013281A MX 2013013281 A MX2013013281 A MX 2013013281A MX 2013013281 A MX2013013281 A MX 2013013281A MX 2013013281 A MX2013013281 A MX 2013013281A
Authority
MX
Mexico
Prior art keywords
cathepsin
treatment
heart failure
pulmonary hypertension
prophylaxis
Prior art date
Application number
MX2013013281A
Other languages
English (en)
Inventor
Heinrich Meier
Stefan Golz
Martina Delbeck
Hubert Truebel
Andreas Geerts
Thomas Mondritzki
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MX2013013281A publication Critical patent/MX2013013281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de inhibidbres de la catepsina K y/o catepsina S en un procedimiento para el tratamiento y/o la profilaxis de hipertensión pulmonar y/o insuficiencia cardiaca.
MX2013013281A 2011-05-16 2012-05-11 Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca. MX2013013281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11166229 2011-05-16
PCT/EP2012/058773 WO2012156311A1 (en) 2011-05-16 2012-05-11 Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure

Publications (1)

Publication Number Publication Date
MX2013013281A true MX2013013281A (es) 2013-12-06

Family

ID=46085031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013281A MX2013013281A (es) 2011-05-16 2012-05-11 Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca.

Country Status (15)

Country Link
US (1) US9943522B2 (es)
EP (1) EP2709602B1 (es)
JP (1) JP6000340B2 (es)
KR (1) KR20140034821A (es)
CN (1) CN103687593B (es)
AU (1) AU2012257779A1 (es)
BR (1) BR112013029672A2 (es)
CA (1) CA2835913A1 (es)
ES (1) ES2648819T3 (es)
IL (1) IL229312A0 (es)
MX (1) MX2013013281A (es)
RU (1) RU2013155509A (es)
SG (1) SG194842A1 (es)
WO (1) WO2012156311A1 (es)
ZA (1) ZA201308391B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194842A1 (en) 2011-05-16 2013-12-30 Bayer Ip Gmbh Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
CN103381152A (zh) * 2013-02-05 2013-11-06 吉林省金梓源生物科技有限公司 杨梅素作为组织蛋白酶k抑制剂的用途
US11766467B2 (en) 2017-09-01 2023-09-26 University Of Wyoming Methods of treating wounds using cathepsin K inhibitors
US10758559B1 (en) 2017-09-01 2020-09-01 University Of Wyoming Targeting cathepsin K to facilitate wound healing
CN109864990B (zh) * 2017-12-05 2022-07-15 中国医学科学院药物研究所 巴利卡替在制备抗丝状病毒感染药物中的应用
CN110981937B (zh) * 2018-09-30 2021-11-12 北京和理咨询有限公司 Odn或衍生物的多肽偶合物及其制备方法和应用
WO2022072504A1 (en) * 2020-09-29 2022-04-07 Healion Bio, Inc. Methods and compositions for the treatment of viral diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1022276T3 (da) 1997-09-04 2003-09-29 Nippon Chemiphar Co Epoxysuccinamidderivater
AU768565B2 (en) 1998-12-23 2003-12-18 Smithkline Beecham Corporation Protease inhibitors
DK1178958T3 (da) 1999-03-15 2004-06-21 Axys Pharm Inc N-cyanomethylamider som proteaseinhibitorer
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
JP2003527429A (ja) 2000-03-21 2003-09-16 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害物質
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20040009171A1 (en) 2001-10-18 2004-01-15 Genentech, Inc. Methods for the treatment of carcinoma
KR100975784B1 (ko) 2002-03-05 2010-08-17 머크 프로스트 캐나다 리미티드 카텝신 시스테인 프로테아제 억제제
JP2006503810A (ja) * 2002-07-04 2006-02-02 アベンティス・ファーマ・ソシエテ・アノニム 新規なアシルヒドラジノチオフェン誘導体、それらの製法、それらの医薬品としての使用、医薬組成物および新規な使用。
US20060020001A1 (en) * 2002-12-23 2006-01-26 Allan Shepard Use of cathepsin k inhibitors for the treatment of glaucoma
DE602004030780D1 (en) 2003-04-25 2011-02-10 Nippon Chemiphar Co Salze von (2s,3s)-3- ää(1s)-1-isobutoxymethyl-3-methylbutylücarbamoylü oxirane-2-carbonsäure
US20080125442A1 (en) * 2005-01-19 2008-05-29 Michael David Percival Cathepsin K Inhibitors and Atherosclerosis
EP1841419A4 (en) * 2005-01-19 2009-02-25 Merck Frosst Canada Ltd INHIBITORS OF CATHEPSIN K AND OBESITY
CN103172568A (zh) 2005-07-06 2013-06-26 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
AU2009237579C1 (en) 2008-04-18 2016-05-12 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
EP2306975A4 (en) * 2008-07-21 2012-10-31 Otonomy Inc CONTROLLED RELEASE COMPOSITIONS MODULATING THE OTIC STRUCTURE AND MODULATING THE NATURAL IMMUNE SYSTEM AND METHODS OF TREATING OTIC DISORDERS
EP2309860B1 (en) * 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
SG194842A1 (en) 2011-05-16 2013-12-30 Bayer Ip Gmbh Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure

Also Published As

Publication number Publication date
EP2709602B1 (en) 2017-08-23
JP2014518868A (ja) 2014-08-07
BR112013029672A2 (pt) 2017-01-17
SG194842A1 (en) 2013-12-30
EP2709602A1 (en) 2014-03-26
CN103687593A (zh) 2014-03-26
WO2012156311A1 (en) 2012-11-22
IL229312A0 (en) 2014-01-30
US20140155383A1 (en) 2014-06-05
KR20140034821A (ko) 2014-03-20
ZA201308391B (en) 2015-02-25
CN103687593B (zh) 2016-09-28
ES2648819T3 (es) 2018-01-08
JP6000340B2 (ja) 2016-09-28
RU2013155509A (ru) 2015-06-27
AU2012257779A1 (en) 2013-11-28
US9943522B2 (en) 2018-04-17
CA2835913A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
PH12015501108B1 (en) Treatment of pulmonary disease
MX2013013281A (es) Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca.
MX2013008737A (es) Formas de dosificacion oral para tasocitinib que comprende liberacion modificada.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2012156537A3 (en) Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of thrombosis and cardiovascular diseases
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
EA201500362A1 (ru) Ингибиторы rho-киназы
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
IN2014CN04634A (es)
EP2595482A4 (en) ALDOSTERONSYNTHASEHEMMER
WO2012156531A9 (en) Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of inflammatory diseases or conditions
JO3450B1 (ar) أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز
WO2012038504A3 (en) Breast cancer therapeutics
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
MX2013011932A (es) Inhibidores de parp para el tratamiento de cipn.
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
PH12016500497A1 (en) Compositions for the treatment of hypertension and/or fibrosis
WO2011083482A3 (en) Method for treatment of psoriasis
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
ZA201307905B (en) Use of fk506 for the treatment of pulmonary arterial hypertension
GB2510524A (en) Pulmonary hypertension
EP2488507A4 (en) NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES
IN2014DN08443A (es)
EP2709630A4 (en) PAR1 INHIBITORS FOR USE IN THE TREATMENT OR PREVENTION OF PARAMYXOVIRIDAE INFECTIONS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal